東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Development of PET Imaging Probes fo...

Al-saden, Noor.

FindBook

Google Book

Amazon

博客來

Development of PET Imaging Probes for Predicting Response of Breast Cancer to Trastuzumab Emtansine (T-DM1).

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Development of PET Imaging Probes for Predicting Response of Breast Cancer to Trastuzumab Emtansine (T-DM1)./
作者:	Al-saden, Noor.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	173 p.
附註:	Source: Dissertations Abstracts International, Volume: 81-06, Section: B.
Contained By:	Dissertations Abstracts International81-06B.
標題:	Pharmaceutical sciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13860265
ISBN:	9781392512340

Development of PET Imaging Probes for Predicting Response of Breast Cancer to Trastuzumab Emtansine (T-DM1).
Al-saden, Noor.

Development of PET Imaging Probes for Predicting Response of Breast Cancer to Trastuzumab Emtansine (T-DM1). - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 173 p.

Source: Dissertations Abstracts International, Volume: 81-06, Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2019.

This item must not be sold to any third party vendors.

The human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20% of breast cancers (BC) and represents an aggressive tumour phenotype conferring a poor prognosis in patients. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for treatment of advanced and metastatic HER2-positive BC. Despite the efficacy of T-DM1 and lower side effects compared to conventional chemotherapy, many eligible patients do not respond. The thesis hypothesis is PET imaging that probes T-DM1 delivery to tumours and its ability to mediate HER2 downregulation would be useful in predicting the response to T-DM1 treatment. An in vivo comparison revealed that 89Zr-DFO-T-DM1 exhibited significantly higher uptake than 89Zr-DFO-trastuzumab in mice with HER2-positive BC xenografts suggesting that 89Zr-DFO-T-DM1 may be more effective to study the delivery of T-DM1 to tumours. The correlation between tumour HER2 density, uptake of 89Zr-DFO-T-DM1, response to T-DM1, and in vitro cytotoxicity to T-DM1 was studied. There was a non-linear but direct correlation between the tumour to blood (T/B) ratios for 89Zr-DFO-T-DM1 and HER2 expression (r2=1.00). There was a direct linear correlation between the T/B ratio for 89Zr-DFO-T-DM1 and tumour doubling ratio (r2=0.97). In addition, in vitro cytotoxicity of T-DM1 demonstrated an inverse correlation with tumour doubling ratio and T/B ratio in mice treated with T-DM1 (r2=1.00). The ability of microPET/CT using 64Cu-NOTA-pertuzumab Fab fragments to detect decreased HER2 expression on tumours in vivo in NOD/SCID mice after T-DM1 treatment was also studied. However, instead of reduced tumour uptake of the imaging probe after T-DM1 treatment, an increase was observed. Further ex vivo analysis of the tumour vasculature showed reduced blood vessel density suggesting that T-DM1 caused normalization of vessels in the tumour microenvironment which increased the uptake of the imaging probe. I conclude that PET is a promising tool for imaging response of HER2-positive BC to treatment with T-DM1.

ISBN: 9781392512340Subjects--Topical Terms:

3173021
Pharmaceutical sciences.
Subjects--Index Terms:

Breast Cancer

Development of PET Imaging Probes for Predicting Response of Breast Cancer to Trastuzumab Emtansine (T-DM1).
LDR:03172nmm a2200337 4500 001 2272469
005 20201105110101.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781392512340
035 $a (MiAaPQ)AAI13860265
035 $a AAI13860265
040 $a MiAaPQ $c MiAaPQ
100 1 $a Al-saden, Noor. $3 3549906
245 1 0 $a Development of PET Imaging Probes for Predicting Response of Breast Cancer to Trastuzumab Emtansine (T-DM1).
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 173 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-06, Section: B.
500 $a Advisor: Reilly, Raymond.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2019.
506 $a This item must not be sold to any third party vendors.
520 $a The human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20% of breast cancers (BC) and represents an aggressive tumour phenotype conferring a poor prognosis in patients. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for treatment of advanced and metastatic HER2-positive BC. Despite the efficacy of T-DM1 and lower side effects compared to conventional chemotherapy, many eligible patients do not respond. The thesis hypothesis is PET imaging that probes T-DM1 delivery to tumours and its ability to mediate HER2 downregulation would be useful in predicting the response to T-DM1 treatment. An in vivo comparison revealed that 89Zr-DFO-T-DM1 exhibited significantly higher uptake than 89Zr-DFO-trastuzumab in mice with HER2-positive BC xenografts suggesting that 89Zr-DFO-T-DM1 may be more effective to study the delivery of T-DM1 to tumours. The correlation between tumour HER2 density, uptake of 89Zr-DFO-T-DM1, response to T-DM1, and in vitro cytotoxicity to T-DM1 was studied. There was a non-linear but direct correlation between the tumour to blood (T/B) ratios for 89Zr-DFO-T-DM1 and HER2 expression (r2=1.00). There was a direct linear correlation between the T/B ratio for 89Zr-DFO-T-DM1 and tumour doubling ratio (r2=0.97). In addition, in vitro cytotoxicity of T-DM1 demonstrated an inverse correlation with tumour doubling ratio and T/B ratio in mice treated with T-DM1 (r2=1.00). The ability of microPET/CT using 64Cu-NOTA-pertuzumab Fab fragments to detect decreased HER2 expression on tumours in vivo in NOD/SCID mice after T-DM1 treatment was also studied. However, instead of reduced tumour uptake of the imaging probe after T-DM1 treatment, an increase was observed. Further ex vivo analysis of the tumour vasculature showed reduced blood vessel density suggesting that T-DM1 caused normalization of vessels in the tumour microenvironment which increased the uptake of the imaging probe. I conclude that PET is a promising tool for imaging response of HER2-positive BC to treatment with T-DM1.
590 $a School code: 0779.
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Medical ethics. $3 526828
653 $a Breast Cancer
653 $a Molecular imaging
653 $a Trastuzumab Emtansine
690 $a 0572
690 $a 0497
710 2 $a University of Toronto (Canada). $b Pharmaceutical Sciences. $3 3170825
773 0 $t Dissertations Abstracts International $g 81-06B.
790 $a 0779
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13860265